Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy

Jean-Marc Lacombe,François Boué,Sophie Grabar,Nathalie Viget,Sandrine Gazaignes,Anne-Sophie Lascaux-Cametz,J. Pacanowski,Marialuisa Partisani,Odile Launay,Sophie Matheron,Eric Rosenthal,E. Rouveix,Pierre Tattevin,Pierre de Truchis,Dominique Costagliola,James J. Goedert

Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy

2013

Jean-Marc Lacombe
François Boué
Sophie Grabar
Nathalie Viget
Sandrine Gazaignes
Anne-Sophie Lascaux-Cametz
J. Pacanowski
Marialuisa Partisani
Odile Launay
Sophie Matheron
Eric Rosenthal
E. Rouveix
Pierre Tattevin
Pierre de Truchis
Dominique Costagliola
James J. Goedert

Objective Determine if incident AIDS-defining Kaposi sarcoma (KS) or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation.

Keywords:

Virology
Prospective cohort study
Pneumocystis jiroveci pneumonia
Immunology
Immune reconstitution inflammatory syndrome
Medicine
Cohort study
Sarcoma
Cart
Viral load
Incidence (epidemiology)
Cohort
Relative risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations